- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00262314
Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients (RENEW)
연구 개요
상태
정황
상세 설명
This phase IV, multicenter, prospective, open-label tolerability and safety monitoring study will enroll a select cohort of 500 multiple sclerosis patients receiving commercially available Novantrone®. The patients will be assessed every 3 months during treatment followed by annual assessment for a total of five (5) years.
The select cohort of MS patients enrolled will have secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting disease (i.e., patients whose neurological status is significantly abnormal between relapses).
The overall objective of this study is to collect data relevant to the tolerability of Novantrone® therapy in patients with multiple sclerosis (MS) using dosing and monitoring recommendations specified in the package insert.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40504-3276
- Registrat Inc
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- To be eligible for inclusion into this study, the subjects must fulfill all of the following criteria:
- Platelet count >100,000 cells/µL
- Granulocyte count > 2000 cells/µL
- Age 18-65 years
- Negative pregnancy test for female patients who are biologically capable of becoming pregnant, even if they are taking birth control
- For patients of reproductive age, agreement to practice effective contraception throughout the study and for 6 months following the last administration of Novantrone®
- Signed Inform Consent.
Exclusion Criteria:
- To be eligible for inclusion in this study the subjects must not meet any of the following criteria:
- Presence of cardiac risk factors:
- History of congestive heart failure
- LVEF < 50% determined by echocardiography or MUGA
- Previous treatment with Novantrone®, other anthracenediones, or anthracyclines
- Prior mediastinal radiotherapy or total lymphoidal irradiation
- AST, ALT, bilirubin > 2x upper limits of normal
- Severe untreated infection (including current urinary tract infection)
- Nursing or pregnant women)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Congestive Heart Failure (Treatment Phase)
기간: up to 36 months
|
Number of patients experiencing congestive heart failure during the treatment phase of the trial
|
up to 36 months
|
Congestive Heart Failure (Annual Follow-Up Phase)
기간: up to 5 years
|
Number of patients experiencing congestive heart failure during the annual follow-up phase of the trial
|
up to 5 years
|
Left Ventricular Ejection Fraction (Treatment Phase)
기간: up to 36 months
|
Number of patients with left ventricular ejection fraction test results that decreased below 50% during the treatment phase of the trial
|
up to 36 months
|
Left Ventricular Ejection Fraction (Annual Follow-Up Phase)
기간: up to 5 years
|
Number of patients with left ventricular ejection fraction test results that decreased below 50% during the annual follow-up phase of the trial
|
up to 5 years
|
Serious Infections (Treatment Phase)
기간: up to 36 months
|
Number of serious infections during the treatment phase of the trial
|
up to 36 months
|
Serious Infections (Annual Follow-Up Phase)
기간: up to 5 years
|
Number of serious infections during the annual follow-up phase of the trial
|
up to 5 years
|
IV Antibiotics (Individual Drugs Unspecified) Utilized Due to Serious Infection (Treatment Phase)
기간: up to 36 months
|
Number of subjects in whom IV antibiotics were utilized due to serious infection during the treatment phase
|
up to 36 months
|
IV Antibiotics (Individual Drugs Unspecified) Utilized Due To Serious Infection (Annual Follow-Up Phase)
기간: up to 5 years
|
Number of subjects in whom IV antibiotics were utilized due to serious infection during the annual follow-up phase
|
up to 5 years
|
Severe Neutropenia (Treatment Phase)
기간: up to 36 months
|
Number of infections associated with severe neutropenia at onset during the treatment phase
|
up to 36 months
|
Severe Neutropenia (Annual Follow-Up Phase)
기간: up to 5 years
|
Number of infections associated with severe neutropenia at onset during the annual follow-up phase
|
up to 5 years
|
Clinical Relapses (Treatment Phase)
기간: up to 36 months
|
Number of clinical relapses reported during the treatment phase of the trial
|
up to 36 months
|
Clinical Relapses (Annual Follow-Up Phase)
기간: up to 5 years
|
Number of clinical relapses reported during the annual follow-up phase of the trial
|
up to 5 years
|
Symptomatic CHF, Left Ventricular Ejection Fraction - Prior to Each Dose • Serious Infections, IV Antibiotics, or Assoc w/ Severe Neutropenia-evaluated. Novantrone Admin - Per PI • SAE, Clinical Relapses
기간: up to 5 years
|
Outcomes are presented separately above apart from adverse events which are presented in the adverse event section
|
up to 5 years
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Randy Bennett, EMD Serono
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 24293
- 19-297
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
다발성 경화증에 대한 임상 시험
-
University Hospital, Montpellier종료됨제1형 당뇨병 | Basal-bolus multiple-dily 인슐린 주사 | 인슐린 펌프(CSII)프랑스